Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | SOD1 | P00441 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5671801 | 0.95 | NQO1 (0.50) | NQO1FGFR1FGFR2SOD1TDP1 | |
| SCHEMBL256791 | 0.86 | NQO1 (0.42) | NQO1FGFR1FGFR2TDP1TSHR | |
| SCHEMBL12093390 | 0.86 | ESR1 (0.50) | NQO1FGFR1FGFR2KAT6AMAPT | |
| SCHEMBL6832377 | 0.84 | MAPT (0.41) | NQO1FGFR1FGFR2KAT6AMAPT | |
| SCHEMBL16184443 | 0.84 | FGFR1 (0.41) | NQO1FGFR1FGFR2SOD1TDP1 | |
| SCHEMBL16961122 | 0.84 | FGFR1 (0.41) | NQO1FGFR1FGFR2SOD1TDP1 | |
| SCHEMBL2395245 | 0.84 | CA12 (0.48) | NQO1FGFR1FGFR2SOD1KAT6A | |
| SCHEMBL13361876 | 0.84 | FGFR1 (0.41) | NQO1FGFR1FGFR2SOD1TDP1 | |
| SCHEMBL12269073 | 0.84 | FGFR1 (0.41) | NQO1FGFR1FGFR2SOD1TDP1 | |
| SCHEMBL2225192 | 0.84 | FGFR1 (0.41) | NQO1FGFR1FGFR2SOD1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377434-B2 | Methods for preparing substituted chromanone derivatives | HANGZHOU DUYI TECHNOLOGY CO. LTD. (CN) | 2022-07-05 | — | — | US | disclosed |
| US-20220024890-A1 | METHODS FOR PREPARING SUBSTITUTED CHROMANONE DERIVATIVES | HANGZHOU DUYI TECHNOLOGY CO. LTD. (CN) | 2022-01-27 | — | — | US | disclosed |
| EP-3666769-A1 | NOVEL CASPASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-06-17 | — | — | EP | disclosed |
| CN-106573927-B | Oxyclohepten-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | 豪夫迈·罗氏有限公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-104640858-B | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | 霍夫曼-拉罗奇有限公司 | 2018-11-06 | — | — | CN | disclosed |
| CN-108715590-A | It can be used as the thiazole carboxamides and pyridinecarboxylic amine compounds of PIM kinase inhibitors | 因赛特公司 | 2018-10-30 | — | — | CN | disclosed |
| CN-105051029-B | Thiazolecarboxamide and picolinamide compounds useful as PIM kinase inhibitors | 因赛特公司 | 2018-07-31 | — | — | CN | disclosed |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-8574814-B2 | Actinic ray-sensitive or radiation-sensitive resin composition, and actinic ray-sensitive or radiation-sensitive film and pattern forming method using the composition | FUJIFILM CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8574814-B2 | Actinic ray-sensitive or radiation-sensitive resin composition, and actinic ray-sensitive or radiation-sensitive film and pattern forming method using the composition | FUJIFILM CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| WO-2009062874-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1979344-A2 | N-(2,3-DIFLUOROPHENYL)-2-[4-({7-METHOXY-5-[(2R)-PIPERIDIN.-2-YLMETHOXY]QUINAZOLIN-4-YL}AMINO)-1H-PYRAZOL-1-YL]ACETAMIDE AND N-(2,3-DIFLUOROPHENYL)-2-[4-({7-ETHOXY-5-[(2R)-PIPERIDIN.-2-YLMETHOXY]QUINAZOLIN-4-YL}AMINO)-1H-PYRAZOL-1-YL]ACETAMIDE FOR USE IN THE TREATMENT OF DISEASE | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-20080194556-A1 | Quinazolines and Their Use as Aurora Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1888572-A1 | QUINAZOLINES AND THEIR USE AS AURORA KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007125398-A2 | : SULFONAMIDE COMPOUNDS AS ANTAGONISTS OF THE N-TYPE CALCIUM CHANNEL | PFIZER JAPAN INC. (JP) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007083096-A2 | N- (2, 3-DIFLUOROPHENYL) -2- [4- ( {7-METHOXY-5- [ (2R) -PIPERIDIN. -2-YLMETHOXY] QUINAZOLI N-4-YL}AMINO) -LH-PYRAZOL-1-YL] ACETAMIDE AND N- (2, 3 -D I FLUORO PHENYL) -2- [4- ( {7-ETHOXY-5- [ (2R) -PIPERIDIN. -2-YLMETHOXY] QUINAZOLIN | ASTRAZENECA AB (SE) | 2007-07-26 | — | — | WO | disclosed |
| WO-2006129064-A1 | QUINAZOLINES AND THEIR USE AS AURORA KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194556-A1 | Quinazolines and Their Use as Aurora Kinase Inhibitors | AURKA, AURKC, AURKB | NQO1 1337/4885FGFR1 739/4885FGFR2 1374/4885 |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DPP4, DPP7, DPP3 | NQO1 1384/4885FGFR1 506/4885FGFR2 1284/4885 |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | NQO1 876/4885FGFR1 2565/4885FGFR2 2789/4885 |
| US-20220024890-A1 | METHODS FOR PREPARING SUBSTITUTED CHROMANONE DERIVATIVES | CBR3, CYP2F1, CBR1 | NQO1 60/4885FGFR1 3592/4885FGFR2 4001/4885 |
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HDAC10, CYP3A4, ECI1 | NQO1 2102/4885FGFR1 1324/4885FGFR2 1007/4885 |
| US-11377434-B2 | Methods for preparing substituted chromanone derivatives | CYP2E1, CYP2F1, CBR1 | NQO1 69/4885FGFR1 3465/4885FGFR2 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.